Skip to Content

Asceniv (immune globulin intravenous) Disease Interactions

There are 3 disease interactions with Asceniv (immune globulin intravenous):


Immune globulin intravenous (applies to Asceniv) HFI

Major Potential Hazard, Moderate plausibility. Applicable conditions: Fructose Intolerance

The immune globulin intravenous (human) injection, Flebogamma 10% DIF and Gammaplex contain sorbitol and should not be administered to patients with hereditary fructose intolerance (HFI).


Immune globulin intravenous (applies to Asceniv) renal disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus, Renal Dysfunction, Sepsis

Renal abnormalities such as acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, including acute renal dysfunction/failure and death have been reported after immune globulin intravenous (IGIV) products. Cases of renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose as a stabilizer. Ensure that patients are not volume-depleted before administering these agents and assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before initiating the infusion and at appropriate intervals thereafter. If renal function deteriorates, consider discontinuation of the product. Periodic monitoring of renal function and urine output is important in patients at increased risk of developing acute renal failure. Administer these agents at the minimum dose and rate of infusion practicable in patients at risk for renal dysfunction or failure.


Immune globulin IV/SQ/IM (applies to Asceniv) thrombosis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus, Cardiovascular Disease, History - Thrombotic/Thromboembolic Disorder, Polycythemia, Hyponatremia

Thrombosis has been reported after treatment with immune globulin products. In general, patients at greatest risk of thromboembolic events are those of advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors; therefore, it is recommended that patients treated with these agents should be monitored for signs and symptoms of thrombosis and assess blood viscosity in patients at risk. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity.

Asceniv (immune globulin intravenous) drug interactions

There are 93 drug interactions with Asceniv (immune globulin intravenous)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.